U.S. Insights: Complex Drug Analogs – Formulation Technologies for Complex Inhaled Drugs

IPD has released its first report in a new series exploring complex drug analogs for formulation technologies, focusing on complex inhaled drugs. Complex inhaled drug products represent a new frontier in pharmaceutical development, offering innovative solutions for respiratory diseases.

While the development of these sophisticated products has traditionally been associated with brand-name pharmaceutical companies, the landscape continues to evolve. Generic manufacturers are increasingly entering this space, bringing competition, affordability, and accessibility to complex inhaled therapies.

In the report, IPD analyzed 35 brand inhaled drugs and their projected competition, finding 15 generic manufacturers likely possessing the complex inhalation formulation technologies to compete in this space. Companies like Lupin, Teva, Amneal, Cipla, Lannett, Sandoz, and Viatris are at the forefront of these technologies among generic drug manufacturers and can be viewed as potential generic competitors for complex inhaled brand drugs that have not yet faced generic competition.

Covered in this report:

- Introduction
- Brand Drugs Utilizing Complex Inhalation Formulation Technologies
- Formulation Technologies by Market Size (Number of Brands and 2022 Gross U.S. Brand Sales in Millions)
- Known Generic Manufacturers Utilizing Complex Inhalation Formulation Technologies
- Number of Complex Inhalation Formulation Technologies by Generic Manufacturer
- Top Seven Generic Manufacturers with Complex Inhalation Formulation Technologies

- Carrier-Based Formulation (Micronized Powder)
- Carrier-Based Formulation (Micronized Powder) Technology: Competitive Analysis
- Market Share Analysis for 2023 (by volume): Advair Diskus (fluticasone propionate; salmeterol xinafoate)

- Microcrystalline Suspension
- Microcrystalline Suspension Formulation Technology: Competitive Analysis
- Market Share Analysis for 2023 (by volume)
- Proventil HFA (albuterol sulfate HFA)
- Proair HFA (albuterol sulfate HFA)

- Capsule-Based Dry Powder Inhaler
- Capsule-Based Dry Powder Inhaler Formulation Technology:
Competitive Analysis
- Market Share Analysis for 4Q 2023 (by volume): Spiriva (tiotropium bromide)

- Phospholipid Co-Suspension
- Phospholipid Co-suspension Formulation Technology: Competitive Analysis